19 results
8-K
EX-2.4
ixt22n6hqn7zr ltjle
29 May 20
Qualigen Therapeutics Announces Merger Closing
5:03pm
S-4/A
EX-10.59
41yjpx6bkytzu
13 Mar 20
Registration of securities issued in business combination transactions (amended)
5:28pm
8-K
EX-2.1
jt6dzj
21 Jan 20
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
9:20am
8-K
EX-2.2
ci9up tsk9
21 Jan 20
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
9:20am
425
EX-2.2
nvt3mhb yjxiommxilwi
21 Jan 20
Business combination disclosure
9:19am
425
EX-2.1
d7jjf
21 Jan 20
Business combination disclosure
9:19am
8-K
EX-99.1
mhcxf
6 Mar 19
Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
7:00am
DRS
jljgkm14
29 Jan 15
Draft registration statement
12:00am
- Prev
- 1
- Next